A5110598412- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Neutropenia and Cancer Infections
- NMR spectroscopy and applications
- Numerical methods for differential equations
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Advanced Neuroimaging Techniques and Applications
- Colorectal Cancer Treatments and Studies
- Oral health in cancer treatment
- Brain Metastases and Treatment
- MRI in cancer diagnosis
- Radiomics and Machine Learning in Medical Imaging
- Head and Neck Cancer Studies
- Fungal Infections and Studies
- Advanced NMR Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Blood disorders and treatments
Fundación Instituto Leloir
2025
University Hospital Complex Of Vigo
2005-2019
Complexo Hospitalario Universitario A Coruña
2019
Spanish Ovarian Cancer Research Group
2013
Galicia Sur Biomedical Foundation
2007
Hospital Xeral Calde
2003
PURPOSE Renal cell carcinoma (RCC) accounts for 2%-3% of adult cancers globally. In Argentina, RCC is the fifth most common cancer, with over 2,000 new patients annually. This study aims to evaluate treatment trends metastatic renal (mRCC) in Argentina. METHODS A retrospective was conducted involving 689 mRCC treated Argentina between 2015 and 2022. The analyzed patterns outcomes time. RESULTS Access combination treatments has increased significantly, 87% receiving such therapies during...
e18052 Background: Bevacizumab, an anti-VEGF monoclonal antibody, improves response rates and prolongs survival in p with non squamous NSCLC when combined carboplatin-paclitaxel PFS cisplatin-gemcitabine. This single-arm, open-labeled phase II trial aims to evaluate the efficacy safety profile of B combination another widely used chemotherapy doublet for NSCLC: cisplatin vinorelbine. Methods: Chemotherapy-naïve diagnosed stage IIIB or IV non-squamous received (80 mg/m2), vinorelbine (25...
7241 Background: Combined thoracic radiation and chemotherapy has become the treatment of choice for unresectable stage III NSCLC, but optimal strategy remain undefined. Methods: 94 patients (pts) with locally advanced IIIAN2/IIIB (no pleural T4), were included in a phase II study scheme induction CPG and, if no surgery, followed by TCRT (Group-1/concomitant) or without (Gr-2) CP. The is: C AUC-5 mgr/iv d1, P 175 mgr/m2/iv G 1000 on d 1 8 every 3 weeks through 2 (Gr1) (Gr2) cycles; Gr-1...